ICU Medical Inc
NASDAQ:ICUI

Watchlist Manager
ICU Medical Inc Logo
ICU Medical Inc
NASDAQ:ICUI
Watchlist
Price: 129.96 USD 3.11% Market Closed
Market Cap: $3.2B

EV/EBIT

38.5
Current
31%
Cheaper
vs 3-y median of 55.7

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
38.5
=
Enterprise Value
$4B
/
EBIT
$109.3m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
38.5
=
Enterprise Value
$4B
/
EBIT
$109.3m

Valuation Scenarios

ICU Medical Inc is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (55.7), the stock would be worth $187.92 (45% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-50%
Maximum Upside
+45%
Average Downside
5%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 38.5 $129.96
0%
3-Year Average 55.7 $187.92
+45%
5-Year Average 51.1 $172.57
+33%
Industry Average 19.2 $64.98
-50%
Country Average 19.6 $66.24
-49%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
$4B
/
Jan 2026
$109.3m
=
38.5
Current
$4B
/
Dec 2026
$356.1m
=
11.2
Forward
$4B
/
Dec 2027
$392.4m
=
10.2
Forward
$4B
/
Dec 2028
$441.5m
=
9.1
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
US
ICU Medical Inc
NASDAQ:ICUI
3.2B USD 38.5 4 383.1
JP
Hoya Corp
TSE:7741
9.8T JPY 34.1 39.1
US
Medline Inc
NASDAQ:MDLN
62.6B USD 0 0
CH
Alcon AG
SIX:ALC
30.7B CHF 29.3 39.2
DK
Coloplast A/S
CSE:COLO B
97.7B DKK 15.8 25.3
US
Align Technology Inc
NASDAQ:ALGN
13.6B USD 19.8 33.1
UK
ConvaTec Group PLC
LSE:CTEC
4.7B GBP 19.2 35.6
CA
Bausch + Lomb Corp
NYSE:BLCO
6B USD 56.3 -16.5
JP
Asahi Intecc Co Ltd
TSE:7747
927.6B JPY 33.8 52.4
KR
HLB Inc
KOSDAQ:028300
8.3T KRW -79.9 -37.7
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.4B USD 18.2 23.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
ICU Medical Inc
NASDAQ:ICUI
Average EV/EBIT: 29.4
38.5
59%
0.7
JP
Hoya Corp
TSE:7741
34.1
N/A N/A
US
M
Medline Inc
NASDAQ:MDLN
Not Available
18%
N/A
CH
Alcon AG
SIX:ALC
29.3
26%
1.1
DK
Coloplast A/S
CSE:COLO B
15.8
7%
2.3
US
Align Technology Inc
NASDAQ:ALGN
19.8
21%
0.9
UK
ConvaTec Group PLC
LSE:CTEC
19.2
21%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
56.3
72%
0.8
JP
A
Asahi Intecc Co Ltd
TSE:7747
33.8
N/A N/A
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -79.9 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
18.2
30%
0.6
P/E Multiple
Earnings Growth PEG
US
ICU Medical Inc
NASDAQ:ICUI
Average P/E: 578.9
4 383.1
606%
7.2
JP
Hoya Corp
TSE:7741
39.1
15%
2.6
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
CH
Alcon AG
SIX:ALC
39.2
32%
1.2
DK
Coloplast A/S
CSE:COLO B
25.3
21%
1.2
US
Align Technology Inc
NASDAQ:ALGN
33.1
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
35.6
41%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -16.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
52.4
40%
1.3
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -37.7 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
23.2
30%
0.8

Market Distribution

Higher than 82% of companies in the United States of America
Percentile
82nd
Based on 8 638 companies
82nd percentile
38.5
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

ICU Medical Inc
Glance View

ICU Medical Inc. emerged as an intriguing player in the healthcare sector, focusing on a mission-critical niche within the industry—safety and efficiency in medical devices for infusion therapy, oncology, and critical care applications. Founded with an innovative spirit, the company carved out a reputation by addressing a key challenge in the medical field: preventing bloodstream infections and the exposure of healthcare professionals to hazardous substances. This focus led to the development of specialized devices such as needle-free connectors and closed system transfer devices, which are integral to minimizing contamination risks. These innovations not only improved patient outcomes but also enhanced the working conditions of medical professionals, underpinning ICU Medical’s growth trajectory. ICU Medical generates revenue by designing and manufacturing these life-saving devices, which are distributed across hospitals and healthcare facilities worldwide. The company's business model revolves around creating products that align with strict regulatory standards, ensuring both safety and superiority in healthcare settings. As they ventured into diverse product lines, such as infusion pumps and systems, the firm leveraged strategic acquisitions to expand market reach and technological capabilities. These initiatives underscored ICU Medical's commitment to operational synergy and product innovation, enabling the company to remain competitive and continue scaling its operations in a constantly evolving healthcare landscape. With a steady focus on both organic growth and strategic partnerships, ICU Medical remains a crucial player in the global health economy, dedicated to advancing patient care and the efficiency of healthcare delivery systems.

ICUI Intrinsic Value
150.3 USD
Undervaluation 14%
Intrinsic Value
Price $129.96
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett